KUALA LUMPUR, Aug 2 (Bernama) -- Neuralstem Inc will allocate US$3 million (RM12.15 million) toward Phase 2 clinical trial evaluating neural stem cell candidate, NSI-566 as a potential treatment for ischemic stroke. (1US$ = RM4.05)
Ischemic stroke is the most common type of stroke, occur as a result of an obstruction within a blood vessel supplying blood to the brain. Approximately 15 million people worldwide suffer stroke -- 87 per cent are ischemic strokes, a statement said.
Chief Scientific Officer of Neuralstem, Dr. Karl Johe said the Phase 2 study will be a randomized, double-blind, controlled study, based on the encouraging results from the open-label Phase 1 safety study.
"It is intended to further test the safety and efficacy of NSI-566 to reverse paralysis in stroke patients with half of their body partially paralyzed, " he added.
The trial will be taking place at Bayi Brain Hospital in Beijing, China, commencing on Aug 1 with Executive Vice President of Asia Operations of Suzhou Neuralstem Ltd, Dr. James Li managing the clinical trial.
--BERNAMA
No comments:
Post a Comment